

Ruth Rodriguez

Search history

Search 1: PN=(wo2013024013) (Results 1)

Search 2: [SP]: 1. process for the preparation of complexes of 68ga wherein the complexing reaction between a chelator-functionalized molecule and 68ga is carried out in a buffer formic acid/formate aqueous solution possibly in the presence of a compound capable of sequestering metal cations, wherein said compound able to sequester metal cations, if used, is added at the beginning of the complexing reaction. 2. process for the preparation of complexes of 68ga wherein the complexing reaction between a chelator-functionalized molecule and 68ga is carried out in a buffered aqueous solution in the presence of a sequestering agent. 3. a process according to claim 1 wherein said chelator-functionalized molecule is chosen in the group consisting of: dota and its derivatives, nota and its derivatives, pcta and its derivatives while said formate is sodium formate. 4. a process according to claim 1 wherein the ratio formic acid/formate in the labeling mixture is comprised between 1 and 3.5 5. a process according to claim 1 wherein said the sequestering agent is chosen in the group consisting of: glycine and other chelating aminoacids, crown ethers and nitrogen crown ethers, eterocyclic organic compound, calixarenes, polydentate chelator, natural chelating agents e.g. catechins, tannin, porphyrinin, linear or macrocyclic chelating agents. 6. a process according to claim 1 wherein the complexing reaction is carried out in a ph range between 3 and 4.5. 7. a process according to claim 6 wherein the reaction ph is more preferably comprised between 3.2 and 4.2. 8. a process according to claim 6 wherein the reaction ph is most preferably between 3.4 and 4.0. 9. process according to claim 1 wherein: a commercial generator of 68ga is eluted with an eluate containing an acid directly into a vial containing buffer formate and a base a chelator-functionalized molecule is added into the vial and the reaction vial is heated for a short time the product is collected. 10. process according to claim 1 wherein: a commercial generator of 68ga is eluted with an eluate containing an acid directly into a vial containing a chelator-functionalized molecule buffer formate and a base are added into the vial and the reaction vial is heated for a short time the product is collected. 11. process according to claim 7 wherein the acid eluate is an aqueous solution of hcl, while the base is an aqueous solution of naoh. 12. a reaction kit comprising: a vial containing the chelator-functionalized molecule and a compound capable of sequestering metal cations a vial or a syringe containing a suitable ultra-pure formic acid/sodium formate mixture. 13. a vial containing a chelator-functionalized molecule, a selected compound capable of sequestering metal cations and a suitable ultra-pure formic acid/sodium formate mixture 14. a reaction kit according to claim 11 and a vial according to claim 13 wherein said vials are siliconized vials. 15. complexes of 68ga, obtained by the process, according to claim 1, characterized in that they contain less than 10 mg/ml formate/formic acid and, if used, less than 100 nmols of sequestering agent. 16. a process according to claim 2 wherein said chelator-functionalized molecule is chosen from the group consisting of: dota and its derivatives, nota and its derivatives, pcta and its derivatives while said formate is sodium formate. 18. a process according to claim 2 wherein the ratio formic acid/formate in the labeling mixture is comprised between 1 and 3.5 (Results 4)

Search 3: TAC=((process OR preparation) AND 68GA complexes) and PN=(wo2013024013) and CPC=(A61K51/0482) (Results 0)

Search 4: TAC=((process OR preparation) AND 68GA complexes) and CPC=(A61K51/0482) (Results 0)

Search 5: TAC=(preparation AND 68GA) and CPC=(A61K51/0482) (Results 23)

Search 6: TAC=(GLP-1 AND FGF21) and CPC=(C07K14/50 AND C07K14/605 AND C07K2319/00) (Results 4)

Title: FUSION PROTEIN REGULATING PLASMA GLUCOSE AND LIPID, ITS PREPARATION METHOD AND USE

Abstract: Source: US2012238496A Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.

Classifications:

International (IPC 8-9): A61K38/22 A61K38/26 A61K47/48 A61P3/00 A61P3/04 A61P3/06 A61P3/10 C07K14/43 C07K14/50 C07K14/575 C07K14/605 C07K17/08 C07K19/00 C12N1/19 C12N1/21 C12N15/06 C12N15/12 C12N15/62 C12N15/63 C12N15/10 C12P21/00 (Advanced/Invention):

A61K38/00 C07K14/50 C07K14/605 (Advanced/Non-invention)

CPC: C07K14/43 A61K38/00 C07K14/50 C07K14/605 C07K2319/00

European: C07K14/50 C07K14/605 K61K38/00 M07K319/00

US: 435/252.3 435/252.8 435/254.2 435/255.1 435/320.1 435/358 435/360 435/69.4
435/69.7 514/11.7 514/9.1 530/308 530/350 530/399 536/23.4



Family:

Publication number	Publication date	Application number	Application date
CN101993485 A	20110330	CN200910104650	20090820
CN101993485 B	20130417	CN200910104650	20090820
CN102770538 A	20121107	CN201080036967	20100312
EP2479193 A1	20120725	EP20100809453	20100315
EP2479193 A4	20130925	EP20100809453	20100315
EP2479193 A9	20130102	EP20100809453	20100315
EP2479193 B1	20150218	EP20100809453	20100315
US2012238496 AA	20120920	US20100391226	20100312
US2012277154 AA	20121101	US20100391097	20100315
US8557771 BB	20131015	US20100391097	20100315
US8809499 BB	20140819	US20100391226	20100312
WO11020319 A1	20110224	WO2010CN71026	20100312
WO11020319 A8	20120315	WO2010CN71026	20100312
WO11020320 A1	20110224	WO2010CN71036	20100315

Priority:

CN200910104650 20090820	CN200910104653 20090820	WO2010CN71036 20100315
WO2010CN71026 20100312	CN201080036967 20100312	

Probable Assignee: LUNAN PHARMACEUTICAL GROUP CORP

Assignee(s): (std): CHEN YONG ; CHONGQING FAGEN BIOMEDICAL INC ; LUO HUA ; YANG LI ; LIU HONGHONG ; FAN KAI ; WANG LIN ; CHONGQING FUJIN BIO PHARM CO LTD ; SHANDONG NEW TIME PHARMACEUTICAL CO LTD ; LUNAN PHARM GROUP CORP ; ZHAO ZHIQUAN ; ZHANG CHUN

Assignee(s): SHANDONG NEW TIME PHARMACEUTICAL CO ; LUNAN PHARMACEUTICAL GROUP CORP ; CHONGQING FUJIN BIO PHARM CO

Inventor(s): (std): CHEN YONG ; CHUN ZHANG ; FAN KAI ; HONGHONG LIU ; HUA LUO ; KAI FAN ; LI YANG ; LIN WANG ; LIU HONGHONG ; LUO HUA ; WANG LIN ; YANG LI ; YONG CHEN ; ZHANG CHUN ; ZHAO ZHIQUAN ; ZHIQUAN ZHAO

Agent(s): GRUENECKER KINKELDEY STOCKMAIR AND SCHWANHAUESSER; GRUENECKER KINKELDEY STOCKMAIR AND SCHWANHAUESSER; PING; ANDREWS KURTH LLP; MASCHOFF BRENNAN; BEIJING HAIHONG JIACHENG INTELLECTUAL PROPERTY AND PARTNERS

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY NZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: FUSION PROTEIN REGULATING PLASMA GLUCOSE AND LIPID, ITS PREPARATION METHOD AND USE

Abstract: Source: EP2468858A1 Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.

Classifications:

International (IPC 8-9): A61K38/26 A61P3/04 A61P3/06 A61P3/10 C07K14/50 C07K14/605 C07K19/00 C12N1/19 C12N1/21 C12N15/06 C12N15/62 C12N15/63 C12N5/10 C12P21/02 (Advanced/Invention); C12R1/19 (Advanced/Non-Invention)

CPC: C07K14/50 A61K38/00 C07K14/605 C07K2319/00

European: C07K14/50 C07K14/605 K61K38/00 M07K319/00



Family:

Publication number	Publication date	Application number	Application date
CN101993496 A	20110330	CN200910104653	20090820
CN101993496 B	20130605	CN200910104653	20090820
EP2468858 A1	20120627	EP20100809452	20100312
EP2468858 A4	20130109	EP20100809452	20100312

Priority:
CN200910104653 20090820 WO2010CN71026 20100312

Probable Assignee: CHONGQING FUJIN BIO PHARM CO LTD

Assignee(s): (std): CHONGQING FAGEN BIOMEDICAL INC ; CHONGQING FUJIN BIO PHARM CO LTD

Assignee(s): CHONGQING FUJIN BIO PHARM CO

Inventor(s): (std): CHEN YONG ; FAN KAI ; LIU HONGHONG ; LUO HUA ; YANG LI ; ZHANG CHUN ; ZHAO ZHIQUAN ; ZHIQUAN ZHAO ; YONG CHEN ; LI YANG ; KAI FAN ; HUA LUO ; HONGHONG LIU ; CHUN ZHANG

Agent(s): GRUENECKER KINKELDEY STOCKMAIR AND SCHWANHAUESSER


Designated states: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Title: DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS

Abstract: Source: US2013129724A The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.

Classifications:

International (IPC 8-9): A61K38/00 A61K38/17 A61K38/18 A61K38/26 A61K47/48 A61P3/00 A61P3/04 A61P3/10 C07K C07K14/435 C07K14/50 C07K14/605 C07K19/00 C12N15/09 (Advanced/Invention); C07K (Subclass/Invention)
CPC: C07K14/50 C07K14/605 C07K2319/00 A61K38/00 C07K14/575
US: 424/134.1 514/9.1 530/387.3 530/399



Family:

Publication number	Publication date	Application number	Application date
AP201407544 A0	20140331	AP20140007544	20120926
AR088165 AA	20140514	AR2012P103552	20120926
AU2012316132 AA	20130404	AU20120316132	20120926
AU2015202305 AA	20150625	AU20150202305	20150501
CA2849760 AA	20140321	CA20122849760	20120926
CL2014000737 A1	20141003	CL20140000737	20140325
CN104024273 A	20140903	CN201280057819	20120926
CO6920258 A2	20140410	CO20140064524	20140326
CR20140141 A	20140715	CR20140000141	20140326
CU20140035 A7	20140828	CU20140000035	20140326
EA201490697 A1	20141128	EA20140090697	20120926
EP2764019 A2	20140813	EP20120773169	20120926
IL231647 A0	20140528	IL20140231647	20140320
JP2014527986 T2	20141023	JP20140532112T	20120926
KR20140069249 A	20140609	KR20147010943	20120926
MA35507 B1	20141002	MA20140036823	20140313
MX2014003676 A1	20150320	MX20140003676	20140326
PE15422014 A1	20141031	PE20140000419	20120926
TW201315742 A	20130416	TW20120135181	20120925
US2013129724 AA	20130523	US20120626207	20120925
UY34347 A1	20130430	UY20120034347	20120925
WO13049234 A2	20130404	WO2012US57371	20120926
WO13049234 A3	20140103	WO2012US57371	20120926

Priority:
US20110539290P 20110926 US20120626207 20120925 WO2012US57371 20120926
AU20120316132 20120926

Probable Assignee: NOVARTIS AG

Assignee(s): (std): BOETTCHER BRIAN R ; CAPLAN SHARI L ; CELLITTI SUSAN E ; DANIELS DOUGLAS S ; LICHT STUART ; HAMAMATSU NORIO ; LOEW ANDREAS ; IRM LLC ; NOVARTIS AG ; GEIERSTANGER BERNHARD HUBERT ; IRM ; WELDON STEPHEN CRAIG ; NOVARTIS INT AG

Assignee(s): NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC ; NOVARTIS INT PHARMACEUTICAL LTD ; NOVARTIS INST FOR FUNCTIONAL GENOMICS INC

Inventor(s): (std): ANDREAS LOEW ; BERNHARD HUBERT GEIERSTANGER ; BOETTCHER BRIAN R ; BRIAN R BOETTCHER ; CAPLAN SHARI L ; CELLITTI SUSAN E ; DANIELS DOUGLAS S ; DOUGLAS S DANIELS ; GEIERSTANGER BERNHARD HUBERT ; GEIERSTANGER BERNHARD HUBERT ; GEIERSTANGER BERNHARDT H ; GEIERSTRANGER BERNHARD HUBERT ; HAMAMATSU NORIO ; LICHT STUART ; LITTI SUSAN E ; LOEW ANDREAS ; NORIO HAMAMATSU ; SHARI L CAPLAN ; STEPHEN CRAIG WELDON ; STUART LICHT ; SUSAN E CELLITTI ; WELDON STEPHEN CRAIG

Inventor(s): BERNHARDT H GEIERSTANGER

Agent(s): GILL CAREY DANIELA; PAGLIERANI PAUL J

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME


Abstract: Source: US2014073563A The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.

Classifications:

International (IPC 8-9): A61K38/18 A61K38/22 A61K38/26 A61K47/48 A61P3/00 A61P3/04 A61P3/06 A61P3/10 A61P9/00 C07K14/50 C07K14/575 C07K14/605 C07K19/00 C12N1/21 C12N15/12 C12N15/16 C12N15/62 C12N15/70 C12P21/02 (Advanced/Invention)

CPC: C07K14/50 C07K14/605 A61K38/1825 A61K38/26 C07K14/57563 C07K2319/00 C07K2319/30 C07K2319/31 C07K2319/50 C07K2319/90 A61K47/48215 C07K19/00

US: 435/252.33 435/254.2 435/320.1 435/348 435/69.7 514/5.3 514/6.7 514/6.9 514/7.2 514/7.4 514/9.1 530/387.3 530/399 536/23.4



Family:

Publication number	Publication date	Application number	Application date
AU2013311777 AA	20140313	AU20130311777	20130904
CA2880929 AA	20150204	CA20132880929	20130904
CN104736558 A	20150624	CN201380046749	20130904
DOP20150020 A	20150415	DO20150000020	20150205
EP2892919 A1	20150715	EP20130758851	20130904
KR20150043505 A	20150422	KR20157007317	20130904
PE06482015 A1	20150525	PE20150000288	20130904
TW201414750 A	20140416	TW20130132110	20130906
US2014073563 AA	20140313	US20130019735	20130906
UY35018 A1	20140331	UY20130035018	20130906
WO14037373 A1	20140313	WO2013EP68239	20130904

Priority:

EP20120306072 20120907 WO2013EP68239 20130904 EP20130758851 20130904

Probable Assignee: SANOFI

Assignee(s): (std): BOSCHEINEN OLIVER ; DREYER MATTHIAS ; HABERMANN PAUL ; LANGER THOMAS ; SCHAEFER HANS LUDWIG ; SOMMERFELD MARK ; SANOFI SA

Assignee(s): SANOFI

Inventor(s): (std): BOSCHEINEN DR OLIVER ; BOSCHEINEN OLIVER ; DREYER DR MATTHIAS ; DREYER MATTHIAS ; HABERMANN DR PAUL ; HABERMANN PAUL ; LANGER DR THOMAS ; LANGER THOMAS ; SCHAEFER DR HANS LUDWIG ; SCHAEFER HANS LUDWIG ; SCHAEFER HANS LUDWING ; SOMMERFELD DR MARK ; SOMMERFELD MARK

Inventor(s): THOMAS LANGER ; MARK SOMMERFELD ; MATTHIAS DREYER ; OLIVER BOSCHEINEN ; PAUL HABERMANN ; HANS LUDWING SCHAEFER ; DR HANS LUDWIG SCHAEFER ; DR MARK SOMMERFELD ; DR MATTHIAS DREYER ; DR OLIVER BOSCHEINEN ; DR PAUL HABERMANN ; DR THOMAS LANGER

Agent(s): TIMMERBEIL BJOERN

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW